RankAlpha logo
Back to Rankings

VOR

Vor BiopharmaD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart

AI scenario view

RankAlpha Sentiment Codex
B+
Bull case
0%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-09-27 · RankAlpha Sentiment Codex
Most likely
B
Base case
1%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-09-27 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-27 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-27
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+48.7
Score

AI commentary

The September 8 company announcement is a positive enrollment milestone, not a clinical readout. Stored coverage reported an initial 1.2% share decline after the August Q2 release, but the packet does not establish a sustained post-announcement reaction. Post-print analyst revisions, options, short-interest, social, and employee measures are unavailable; zeroes above are placeholders, not measured neutral readings. Low coverage and the negative deterministic return prior favor monitoring rather than an upgrade.

RankAlpha Sentiment Codex - 2026-09-27
Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2027-06-30eventUPSTREAM MG Phase 3 topline resultsHigh impact

Vor completed enrollment in September and still expects results from the 24-week primary endpoint in the first half of 2027. This is the principal clinical and valuation risk; completion of enrollment does not establish efficacy or safety. [#PR-2026-09-08] https://ir.vorbio.com/news-releases/news-release-details/vor-completes-enrollment-global-phase-3-upstream-mg-trial-and

2027-06-30eventPlanned UPSTREAM oMG first patient dosingHigh impact

Vor plans to start its global Phase 3 ocular myasthenia gravis trial and dose the first patient in the first half of 2027. Initiation would expand development but also add spending before clinical validation. [#PR-2026-09-08] https://ir.vorbio.com/news-releases/news-release-details/vor-completes-enrollment-global-phase-3-upstream-mg-trial-and

2027-09-27catalystUPSTREAM SjD Phase 3 enrollment progressHigh impact

Enrollment was ongoing in the global Sjögren’s disease trial at the August financial update. A readout date was not provided, so this remains an execution item rather than a dated data catalyst. [#PR-EARNINGS-2026-08-11] https://ir.vorbio.com/news-releases/news-release-details/vor-bio-reports-second-quarter-2026-financial-results-and

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-09-27 • Updated nightlySource: Internal modelMethodology